ACA
AZN icon

Avoro Capital Advisors’s AstraZeneca AZN Stock Holding History

Avoro Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-375,150
Closed -$26.2M – 47
2018
Q1 		$26.2M Hold
375,150
– – 1.25% 25
2017
Q4 		$26M Buy
+375,150
New +$25.3M 1.69% 20

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Avoro Capital Advisors's AZN Position: Q2 2018 in Review

Avoro Capital Advisors sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 375,150 shares — an estimated $26.2M sold.

Avoro Capital Advisors first reported a position in AZN in Q4 2017 and held it in 2 quarters. The position peaked at $26.2M in Q1 2018. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

  • Avoro Capital Advisors reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 375,150 AstraZeneca shares in Q2 2018, an estimated $26.2M.
  • Avoro Capital Advisors first reported a position in AstraZeneca in Q4 2017 and held it in 2 quarters.
  • Avoro Capital Advisors's AstraZeneca position peaked at $26.2M in Q1 2018.
  • 531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.